← All trials
NCT01853124
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2013
- Primary completion
- May 1, 2017
- Completion date
- Jul 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 886
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of CalgaryLead sponsor
- University of CalgaryOverall official - principal investigator
- University of CalgarySponsor investigator
- University of MontrealCollaborator
- University of TorontoCollaborator
- Dalhousie UniversityCollaborator
- University of CalgaryCollaborator
- University of OttawaCollaborator
- Lallemand SASCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- University of Western OntarioCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.